Teleflex (NYSE:TFX) may be getting out of the orthopedic OEM business, but it’s still going strong with its other OEM businesses, as evidenced by a newly expanded facility in Jaffrey, N.H., the medical device company opened last week.
Business/Financial News
Wall Street Beat | Earnings Reports | Funding Roundup | Mergers & Acquisitions | Initial Public Offerings | Legal News
CareFusion delays annual report, gets delisting NYSE warning | Wall Street Beat
CareFusion (NYSE:CFN) shares are down slightly today after the medical device company said it would be late in filing its annual report with the SEC, which triggered a delisting warning from the New York Stock Exchange.
CareFusion said it’s negotiating with the securities regulator over how to account for leases of its Pyxis medicine dispensing devices.
How to capitalize on the Fed’s QE3 | Wall Street Beat
Federal Reserve chairman Ben Bernanke said today that the bank will undertake a 3rd round of quantitative easing, as the Fed looks to strengthen the nascent economic recovery.
The so-called "QE3" plan will see the Fed buy up about $40 billion worth of long-term mortgage debt each month, hoping to boost growth and employment.
The move sent stocks up on Wall Street today, with the Down Jones Industrial Average and the S&P 500 each gaining 1.6%.
For Boston Scientific, the growth cup is half full | Wall Street Beat
For Boston Scientific (NYSE:BSX), proving to Wall Street that it’s still capable of growing sales is key to reviving its sagging share price, officials said today.
Medtronic CFO: Size matters
Analyst: St. Jude Medical might have an edge on Volcano in patent spat | Wall Street Beat
Cancer: Accuray’s losses widen as it prepares for “major technology launch”
Meeting: Will CMS limit off-label use of left ventricular assist devices?
The Centers for Medicare & Medicaid Services are likely to leave current payment intact for left ventricular assist devices, but an agenda released ahead of a November meeting hints at possible restrictions on off-label use for the costly devices.
The federal agency plans to meet November 14 to review available evidence on LVADs and discuss how best to optimize outcomes for heart failure patients, especially when it comes to pinpointing which patients are likely to benefit from the procedure.
Medical device M&A: Has CEO turnover stymied acquisitions?
Medical device mergers & acquisition activity is as scarce in 2012 as during the global financial meltdown in 2009, perhaps because of a concurrent flurry of CEO turnovers.
medtech companies have announced $20 billion worth of deals so far for 2012, less than half of the $53.32 billion worth posted in 2011, according to a Thomson Reuters report.
Medtronic: Defibrillator market is stabilizing | Wall Street Beat
Mixed results for HeartFlow’s CT-based FFR tests for coronary artery disease
HeartFlow’s non-invasive fractional flow reserve technology failed to meet pre-determined rates of accuracy in a recent clinical trial, but researchers and clinicians remained optimistic that the new system may yet replace invasive testing for coronary artery disease.
In the DeFACTO study, which enrolled more than 250 patients, FFR based on computed tomography imaging beat invasive FFR in identifying lesions and produced higher per-patient sensitivity.